Provided by Tiger Fintech (Singapore) Pte. Ltd.

Seres Therapeutics

0.6898
+0.05148.05%
Post-market: 0.6600-0.0298-4.32%19:11 EDT
Volume:812.35K
Turnover:548.49K
Market Cap:117.78M
PE:-3.93
High:0.6900
Open:0.6500
Low:0.6400
Close:0.6384
Loading ...

The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable

Simply Wall St.
·
26 Dec 2024

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference

TIPRANKS
·
16 Dec 2024

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

GlobeNewswire
·
16 Dec 2024

Optimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost Confidence

TIPRANKS
·
10 Dec 2024

Seres Therapeutics Shares up 10.2% on 'Breakthrough Therapy' Tag for Blood Infection Treatment

THOMSON REUTERS
·
09 Dec 2024

BUZZ-Seres Therapeutics rises on 'breakthrough therapy' tag for blood infection treatment

Reuters
·
09 Dec 2024

Seres Therapeutics granted Breakthrough Therapy designation for SER-155

TIPRANKS
·
09 Dec 2024

BRIEF-FDA Grants Breakthrough Therapy Designation To Seres Therapeutics’ SER-155

Reuters
·
09 Dec 2024

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)

THOMSON REUTERS
·
09 Dec 2024

Seres Therapeutics Inc - FDA Meeting on Next Study of Ser-155 Expected in Q1 2025

THOMSON REUTERS
·
09 Dec 2024

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

GlobeNewswire
·
09 Dec 2024

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

GlobeNewswire
·
22 Nov 2024

Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)

Simply Wall St.
·
15 Nov 2024

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...

GuruFocus.com
·
14 Nov 2024

Seres Therapeutics Reports Q3 2024 Results and Strategic Progress

TIPRANKS
·
14 Nov 2024

Seres Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
14 Nov 2024